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Abstract
Background: hRad9 is a cell cycle checkpoint gene that is up-regulated in breast cancer. We have
previously shown that the mRNA up-regulation correlated with tumor size and local recurrence.
Immunohistochemical studies were made to better define the role of hRad9  in breast
carcinogenesis.
Methods: Localisation of hRad9 protein were performed on paired tumor and normal breast
tissues. Immunoblotting with and without dephosphorylation was used to define the protein
isolated from breast cancer cells.
Results: Increased hRad9 protein was observed in breast cancer cells nucleus compared to non-
tumor epithelium. This nuclear protein existed in hyperphosphorylated forms which may be those
of the hRad9-hRad1-hHus1 complex.
Conclusion: Finding of hyperphosphorylated forms of hRad9 in the nucleus of cancer cells is in
keeping with its function in ameliorating DNA instability, whereby it inadvertently assists tumor
growth.
Background
Human Rad 9 (hRad9) was originally identified as a struc-
tural homologue of yeast schizosaccharomyces pombe rad
9, which can partially rescue the sensitivity of rad 9 null
yeast to hydroxyurea, radiation damage and the associ-
ated checkpoint defects [1]. One would expect that this
gene functions as a tumor suppressor gene. This is sup-
ported by the finding that hRad9 is a negative co-regulator,
suppressing androgen receptor activation in prostate can-
cer cells [2] and that the mammalian prologue hRad9B is
expressed predominantly in the testis and at a reduced
level in testicular tumors compared to normal adult testis
[3].
Normally, structural damage of DNA by endogenous and
environmental agents is followed by replication check-
point arrest at the G2/M transition in order to allow for
repair before proceeding in the cell cycle. Also with exces-
sive DNA damage, apoptosis of the cell occurs [4]. The
loss of proper response to DNA damage leads to genomic
instability such as gene mutations, incomplete replication
and the loss or gain of chromosomes to future genera-
tions. These genetic aberrations may cause loss of growth
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inhibition in normally quiescent cells and result in car-
cinogenesis [5].
However, in established cancer cells, such DNA repair sys-
tem may prevent further DNA damage in their progeny
and decrease in apoptosis resulting in enhancement of
tumor growth. Hence, the phosphorylated forms of hRad9
have been identified in the tumor cells nucleus of non-
small cell lung carcinoma (NSCLC) and increased expres-
sion of hRad9 was related to increased tumor cell prolifer-
ation [6]. However, sequencing of the hRad9 gene failed to
identify any mutation although a non-synonymous single
nucleotide polymorphism (SNP), His239Arg, was found
to be associated with lung adenocarcinoma [7]. We have
also demonstrated previously overexpression of Rad9
mRNA in a number of primary breast tumors and the
increased Rad9 mRNA was correlated with an increased
risk of local recurrence and tumor proliferation, suggest-
ing that Rad9 is an oncogene in breast cancer [8].
hRad9 is a nuclear protein that interacts with hRad1 and
hHus1 to form a hetero-trimeric complex (the 9-1-1 com-
plex) which is then loaded onto DNA [9]. The C-terminal
domain of hRad9 contains phosphorylation sites and
hyperphosphorylation of hRad9 occurs in response to
DNA damage [10]. It also contains a nuclear localization
sequence (NLS) that targets the hRad9 protein into the
nucleus [11]. Presumably the C-terminal domain is essen-
tial for transport of the 9-1-1 complex from the cytoplasm
into the nucleus, for activation of the G2 checkpoint sig-
nalling cascade [12]. Additionally, hRad9 contains a Bcl-2
homolog 3 (BH3)-like domain at its NH2 terminus that
can bind the anti-apoptotic proteins Bcl2 and Bcl-xL,
thereby promoting apoptosis when DNA repair fails [13].
Thus, in addition to its checkpoint control function,
hRad9 may play a role in regulating apoptosis.
To further examine the role of hRad9 in breast cancer
cells, we now report on the histologic expression of the
hRad9 protein and its different molecular forms in pri-
mary breast cancer and normal tissues.
Methods
Thirty-seven sets of breast tumor and adjacent normal
breast tissues obtained during surgical resection were used
in this study; with ethics approval from the Institutional
Review Board of the University of Hong Kong/Hospital
Authority Hong Kong West Cluster (Ref No. UW 06-036
T/1061) and according to the Declaration of Helsinki.
Upon surgical resection, part of the samples was
immersed in RNAlater (Ambion, Inc., Austin, Texas) and
incubated overnight at 4°C before long-term storage at -
80°C. Other portions of these samples were fixed with
10% (volume/volume) neutral-buffered formalin over-
night and then embedded in paraffin.
Of the 37 paired breast tumor and adjacent normal breast
tissues, 22 cases were previously determined by quantita-
tive PCR [8] as having a relative hRad9 mRNA level of > 2
in the tumor sample (compared to adjacent normal breast
tissue) and 15 cases having hRad9 mRNA level < 2. These
were designated as Group 1 and Group 2 respectively.
Immunohistochemistry
Immunohistochemical studies were performed on paraf-
fin sections using the avidin-biotinylated peroxidase com-
plex method (Dako Cytomation A/S, Glostrup, Denmark)
according to the manufacturer's instruction. Briefly, sec-
tions were deparaffinised and rehydrated through ethanol
series (99%, 95% and 80% Ethanol). Antigen retrieval
was made by heating for 1 min in Tris/EDTA buffer in a
pressure cooker. Sections were incubated for 20 min with
3% hydrogen peroxide in water, to remove endogenous
peroxidase activities and for a similar period with diluted
blocking solution (10 mg bovine serum albumin, 10%
normal goat serum and 1 μl Triton X-100 in Tris buffer
saline, TBS). The sections were initially incubated with
diluted (1:75) Rad9 antibody (M-389, Santa Cruz Bio-
technology, CA, USA) at 4°C overnight, and rinsed with
TBS, before incubation with a biotinylated second anti-
body solution (KO492, Dako, 1:100 dilution) at 37°C for
30 min. The bound antigen was visualized using strepta-
vidin-biotin-hydrogen peroxide complex with 3, 3'-
diamobenzidine tetrachloride (DAB) as substrate and
counterstained with Mayer's haematoxylin. Staining dis-
tribution and the intensity of staining were scored sepa-
rately by two persons, blinded to the pathology of the
sections. Each slide was scored for cytoplasmic and
nuclear staining of the cancer and normal cells. Semi-
quantitative grading was made according to the following
scores: 0 (negative); 1+ (weak positive), 2+ (moderate
positive) and 3+ (strong positive).
Western immunoblotting
One hundred mg of frozen tissue was homogenised in
500 μl of Laemmli sample buffer (Biorad, CA, USA) con-
taining 100 mM dithiothreitol at 4°C using a Polytron
generator. Extracts were centrifuged at 10,000 g × 5 min at
4°C to remove debris and 10 μl of the supernatant heated
in a boiling water bath for 5 min before subjecting to
sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis (0.1% SDS-10% PAG). The proteins were trans-
ferred to nitrocellulose membrane by electroblotting. The
membrane was blocked with 5% non-fat milk, 0.05%
Tween 20 in phosphate buffer saline for 1 hr at room tem-
perature, to reduce non-specific protein binding. It was
then incubated with anti-Rad9 (at 1:1000 dilution, Santa
Cruz Biotechnology) in a sealed bag at 4°C overnight, fol-
lowed by incubation with a second antibody (1:3000
dilution), again at 4°C for 1 hr before visualization using
the ECL system (GE Healthcare Ltd, Little Chalfont, UK).BMC Cancer 2008, 8:196 http://www.biomedcentral.com/1471-2407/8/196
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Phosphatase experiment
To demonstrate that hRad9 protein in breast cancer cells
is in phosphorylated forms, 100 mg amounts of frozen
tissue were extracted as previous in the presence of pro-
tease inhibitors (protease inhibitor cocktail, set III; EMD
Biosciences Inc, CA, USA). Forty mg of protein were
treated with λ phosphatase (New England Biolabs, Bev-
erly, MA, USA) in accordance with the manufacturer's
instruction. The treated samples were heated at 95°C × 5
min, then on ice × 5 min before subjecting to SDS-10%
PAG electrophoresis. Electroblotting and immunostain-
ing were performed as described previously (vide supra).
Results
Localization of hRad9 protein in breast samples
Figure 1 showed tumor cells and non-tumor cells stained
for hRad9 protein.
Whilst hRad9 protein was observed in similar amounts in
the cytoplasm of both normal cells and cancer cells in all
specimens studied, the staining in the nucleus of cancer
cells were significantly higher (p < 0.001) and the com-
bined cytoplasmic and nuclear scores were also higher in
the cancer cells (p = 0.002) (Table 1). Furthermore, the
nuclear score found in tumor samples with increased
hRad9 mRNA (Group 1), was significantly higher com-
pared to tumor samples with normal hRad9 mRNA level
Immunohistochemical stain for hRad9 protein in two breast samples Figure 1
Immunohistochemical stain for hRad9 protein in two breast samples (case 8 and case 13) taken during surgical 
resection. Paired tumor (left panel) and normal (right panel) breast tissue was studied. In both cases, tumor cell nucleus stained 
more heavily (2+) compared to normal cell nucleus (0 and 1+).BMC Cancer 2008, 8:196 http://www.biomedcentral.com/1471-2407/8/196
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(Group 2), while the cytoplasm scores were similar (Table
2).
Western blot and λ phosphatase treatment
Western blot analysis showed at least four different spe-
cies of hRad9 protein in a breast tumor sample with posi-
tive nuclear staining, with molecular weight ranging from
65 to 45 KDa. Whereas in MDA-231 breast cancer cell line,
the hRad9 protein was mainly 50 and 45 KDa. Dephos-
phorylation of hRad9 protein extracted from both the
tumor sample with nuclear staining and the MDA-231
cancer cell line with λ phosphatase yielded an additional
48 KDa species. The control tumor sample (which had no
nuclear hRad9 staining), did not produce any 48 KDa spe-
cies even upon treatment with 500 units of λ phosphatase
(Figure 2).
Discussion
Breast cancer cells were demonstrated in this study to have
significantly increased hRad9 protein staining in their
nuclei. This is especially marked in those shown to have
increased hRad9 mRNA levels. We have shown previously
that, clinico-pathologically, increased tumor size and
chance of local recurrence were positively related to
mRNA level of the tumor [8]. Hence the higher levels of
hRad9 protein in the tumor nuclei may indicate a poorer
clinical outcome of the breast cancer. This finding is sim-
ilar to Maniwa et al.'s work on NSCLC [6]. Concomitant
with the increased nuclear staining of hRad9, Maniwa's
group demonstrated an increase in phosphorylated check-
point kinase-1 (ChK1), suggesting that this is a physio-
logic response of the DNA damage checkpoint signaling
pathway to genetic aberrations that occur in tumor cells.
Maniwa et al. initially postulated that a mutated form of
hRad9 may be present in the malignant cells, similar to
the presence of mutated p53 that were over-expressed in
the nucleus of primary lung cancer [14]. However,
sequencing of hRad9  gene in NSCLC samples did not
reveal any mutation [7]. We have previously shown that
increased in hRad9 messenger in breast cancer was either
due to gene amplification or hypermethylation in intron
2 of hRad9 gene, a silencer [8], resulting in increased tran-
scription. Thus it would appear that the increased expres-
sion of hRad9  in tumor cells nuclei in both lung and
breast cancers may serve to enhance DNA repair.
In human breast cancer cells, hRad9 exists in various
forms, with molecular weights of 65, 50 and 45 KDa. In
contrast, MDA-231 human breast cancer cell line contains
the 50 and 45 KDa bands only. The theoretical molecular
weight of hRad9 is 45 KDa [15] and the 65 and 50 KDa
forms most likely represent hyperphosphorylated hRad9
and its hRad9-hRad1-hHus1 (9-1-1) complex. Upon
dephosphorylation of this protein with λ phosphatase, an
increasing amount of 50 KDa and a new 48 KDa form
were noted. The 48 KDa form was only observed in MDA-
231 cell line and in the breast tumor sample with nuclei
staining (Figure 2; Panel A) and was absent in the tumor
sample without nuclei staining (Figure 2; Panel B). Hence
the larger hRad9 proteins, representing 9-1-1 complexes,
are probably hyperphosphorylated as a cellular response
to DNA damage in the nucleus [6]. Our findings of
increased nuclear localization of hRad9 in breast cancer
compared with non-tumor epithelium, which correlated
with increased hRad9  mRNA expression, suggests that
nuclear localization of hRad9 may be a response to DNA
damage. It is most possible therefore that hRad9 protein
functions in the nucleus of cancer cells to ameliorate DNA
instability and inadvertently assists tumor growth. Further
functional study of the hRad9 and its signalling pathway
Table 1: Semiquantitative scores of immunoreactive hRad9 protein in sections of all tumor samples studied
N Cytoplasmic score Nuclear score Cytoplasmic + nuclear score
Normal cells 37 1.402 ± 0.532* 0.111 ± 0.340 1.513 ± 0.741
Cancer cells 37 1.333 ± 0.560 0.861 ± 0.661 2.208 ± 1.091
Paired t test 0.502 7.314 3.382
p 0.0619 0.000 0.002
*Mean ± SD
Table 2: Immunoreactive hRad9 protein scores in two groups of breast cancers
N mRNA ratio* (Cancer/normal cells) Cytoplasmic score Nuclear score Cytoplasmic + nuclear score
Group 1 22 5.375 ± 2.443** 1.48 ± 0.663 1.16 ± 0.497 2.659 ± 1.039
Group 2 15 1.383 ± 0.435 1.20 ± 0.414 0.47 ± 0.667 1.666 ± 0.975
t 7.490 0.436 3.619 2.921
p < 0.001 0.16 0.001 0.006
*Quantitative PCR for these samples was performed in a previous study [8].
**Mean ± SD.BMC Cancer 2008, 8:196 http://www.biomedcentral.com/1471-2407/8/196
Page 5 of 6
(page number not for citation purposes)
would be worthwhile to elucidate its role in breast cancer
development and progression.
Conclusion
Finding of hyperphosphorylated forms of hRad9 in the
nucleus of cancer cells is in keeping with its function in
ameliorating DNA instability, whereby it inadvertently
assists tumor growth.
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Western blot showing hRad9 protein Figure 2
Western blot showing hRad9 protein extracted from MDA231 breast cancer cells, breast tumor sample with nuclear 
staining of hRad9 (A) and a control tumor sample with no nuclear staining (B). The relative position for molecular weights (in 
KDa) are indicated on the right. Protein extracts were treated with λ phosphatase (100 and 500 units respectively).Publish with BioMed Central    and   every 
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